Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000921895-25-001849
Filing Date
2025-06-26
Accepted
2025-06-26 17:36:17
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12032
2 JOINT FILING AGREEMENT ex99113gnew11527aytu_062625.htm EX-99.1 6922
  Complete submission text file 0000921895-25-001849.txt   20965
Mailing Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237
Business Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 (720) 437-6580
AYTU BIOPHARMA, INC (Subject) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88813 | Film No.: 251081506
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 6810 LYONS TECHNOLOGY CIRCLE SUITE 160 COCONUT CREEK FL 33076
Business Address 6810 LYONS TECHNOLOGY CIRCLE SUITE 160 COCONUT CREEK FL 33076 631-863-3100
Philotimo Fund, LP (Filed by) CIK: 0001688522 (see all company filings)

EIN.: 000000000 | State of Incorp.: FL | Fiscal Year End: 1231
Type: SCHEDULE 13G